Month: August 2024

When it comes to the "P" in the THP regimen for HER2-positive breast cancer, do you prefer Pertuzumab or Pyrotinib? At the 2024 Breast Cancer Summer Forum · Northern Salon's "Root Cause" session, Dr. Zhanhong Chen from Zhejiang Cancer Hospital and Dr. Rui Ge from Huadong Hospital Affiliated to Fudan University shared their perspectives. Professor Chen advocated for Pyrotinib, while Professor Ge favored Pertuzumab. After the session, Oncology Frontier invited both experts to elaborate on their viewpoints.

A century ago, Paul Ehrlich, the father of German immunology, proposed the concept of the "Magic Bullet," which targets toxic drugs to microorganisms or tumor cells. With continuous technological breakthroughs, Antibody-Drug Conjugates (ADCs) have seen explosive approval. These drugs combine specific monoclonal antibodies with highly active cytotoxic drugs via linkers, balancing the specificity of targeted therapies with the efficacy of cytotoxic drugs. ADCs have shown strong activity in anti-tumor therapy due to their unique design and pharmaceutical properties, with significant advantages in targeting specificity and reducing side effects. Particularly in breast cancer, ADCs like T-DXd have brought significant survival benefits to advanced patients, transforming the clinical treatment landscape of breast cancer. Despite their impressive clinical performance, ADCs still face the challenge of treatment resistance. Fully understanding the mechanisms of ADC resistance is clinically significant as it guides the development of subsequent treatment strategies. Oncology Frontier invited Dr. Wenxing Qin from Fudan University Shanghai Cancer Center to systematically review the progress in ADC resistance mechanisms and feasible response strategies.

At the 2024 China Anti-Cancer Association (CACA) Integrated Breast Cancer Conference, Dr. Yongsheng Wang from Shandong Cancer Hospital elaborated on new concepts in regional treatment for breast cancer. He emphasized that local regional treatment for breast cancer patients should comprehensively consider the risk of recurrence and metastasis, the efficacy and adverse effects of systemic treatment, and the efficacy and adverse effects of local regional management. Professor Wang also proposed a new definition for axillary lymph node negativity and discussed individualized adjuvant radiotherapy strategies for patients with positive sentinel lymph node biopsy and new strategies for managing the internal mammary region. Following the conference, Oncology Frontier invited Professor Wang for an in-depth discussion on regional lymph node treatment.

Cancer-related anemia (CRA) encompasses anemia that occurs in cancer patients during disease progression or treatment, including non-chemotherapy-related CRA and chemotherapy-induced anemia (CIA). With the increase in chemotherapy treatments, the incidence of anemia is significant, with over 90% of patients not receiving any corrective treatment. To gain a comprehensive understanding of the current practices and perceptions of Chinese clinicians in managing CIA and to improve the management level of CIA in China, Oncology Frontier initiated a "Survey on Chemotherapy-Induced Anemia in Cancer Patients," collecting 308 questionnaires from 28 provinces and cities across the country. The survey revealed that although the current management concepts of CIA in China still differ from existing guidelines, Chinese clinicians' awareness of CIA management is continually strengthening, contributing to the standardization of management for anemia related to new anti-cancer therapies.